In successfully implementing the company’s second New York-based production line, GrapheneCA has proved scalability, and is already making known its plans to inaugurate a production facility for cosmetics and pharmaceutical grade graphene in Canada by the end of 2019.
“Not only has GrapheneCA succeeded in producing pure graphene that is suitable for medical and pharmaceutical applications, but it has standardized its manufacturing process and is deploying efforts to provide whole package solutions, using its own graphene technology, which industries need and are looking for,” explained Alex Hamouti, Montreal-based Head of Cosmetic and Dental Hygiene Development for GrapheneCA.
“To be suitable for cosmetics and pharmaceutical use, graphene must have a very high level of purity and be non-toxic; this constraint is of paramount importance, one to which we respond with a highly efficient proprietary production process,” he went on to say.
“Graphene has unique properties that make it an extremely promising material for innumerable biotech applications; what interests these industries in particular is graphene’s antibacterial characteristics, its conductive and thermal properties, as well as its uncanny ability to facilitate absorption of active ingredients. Recent research also demonstrates that graphene is highly biocompatible.”